Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinib
- 1 November 2025
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 210, 108808
Abstract
No abstract availableKeywords
Funding Information
- Chinese University of Hong Kong (4054725)
This publication has 19 references indexed in Scilit:
- Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trialeClinicalMedicine, 2024
- Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSAAnnals of Oncology, 2024
- Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 studyThe Lancet, 2023
- Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLCNew England Journal of Medicine, 2023
- Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort studyLung Cancer, 2023
- Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLCNew England Journal of Medicine, 2020
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non–small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor MutationClinical Lung Cancer, 2017
- Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failureLung Cancer, 2011